Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape.

Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria

Founded in Indianapolis in 1876, Eli Lilly and Co. (LLY, Financial) is one of the world's top pharmaceutical companies. Its products are manufactured and distributed in more than 100 countries through facilities in the U.S., Europe and Asia.

From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles

INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Sept.

Lilly Declares Third-Quarter 2024 Dividend

ResMed

Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have an impact on ResMed's future business.

Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling

Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea.

Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea

ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.

Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again

Chipotle

General Electric

General Motors

Micron Technology

Netflix

NVIDIA

“Bullish momentum remains intact for the S&P 500 and Nasdaq, but near-term overbought conditions coupled with deteriorating breadth make equities vulnerable to a pullback or correction,' said Craig Johnson at Piper Sandler.

8 Stocks Rising Impressively Alongside Megacaps

Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.

ResMed Stock Is Sinking. Blame Lilly's Zepbound Trials for Sleep Apnea.

Broadcom

Visa

The AI driven massive surge in Nvidia Corp has pushed it market cap well above the $3.0 trillion mark. Meanwhile, these three stocks look ripe to hit their first trillion in valuation.

Buy these 3 stocks that could soon join the trillion-dollar club

Eli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials.

Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says

In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as defined by apnea-hypopnea index and Epworth Sleepiness Scale measures Lilly submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA) and will initiate submissions for other global regulatory agencies in the coming weeks INDIANAPOLIS , June 21, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo.

Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution

Eli Lilly said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year. The company released additional data from two late-stage trials showing that Zepbound helped resolve obstructive sleep apnea in almost half of patients.

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

AbbVie

Novo Nordisk

Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies shifted back toward chronic diseases like diabetes, cancer, and heart disease.

3 Biotech Stocks to Buy Now: June 2024

Costco

Wingstop

Overvalued stocks are prevalent in today's market. Based on the historical ratio of total market cap over GDP (currently at 193.4%), the Buffett Indicator suggests that the U.S. stock market is significantly overvalued.

Hype Busters: 3 Overvalued Stocks Ready for a Reality Check

The latest trading day saw Eli Lilly (LLY) settling at $885.99, representing a -0.61% change from its previous close.

Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note

Lilly's Alzheimer's disease drug donanemab could receive FDA approval by year-end. Donanemab would likely be covered by Medicare if approved.

Eli Lilly Has a New Drug That Could Push the Stock Higher

Dell Technologies

Disney

Alphabet

Riot Blockchain

Investors searching for stocks that will grow their portfolio and provide a strong return on capital should pay attention to analyst ratings, particularly the ones placed on strong buy growth stocks. Analysts are selective about the stocks they give their highest ratings to and are growing increasingly picky as the market rallies to all-time highs.

Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now

Eli Lilly's stock is expensive and is trading at around all-time highs. That's thanks to its promising weight-loss and diabetes drugs, Zepbound and Mounjaro.

Eli Lilly's Growth Prospects Just Got a Huge Upgrade

Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have been left behind, particularly those in the ‘defensive' space, such as the healthcare sector.

Eli Lilly's Stock Surge Driven by GLP-1 Demand

U.S. drugmaker Eli Lilly on Thursday said it was suing six more U.S. medical spas, wellness centers and other entities for selling products claiming to contain tirzepatide, the active ingredient in its popular diabetes drug Mounjaro.

Lilly files additional lawsuits over US sales of counterfeit Mounjaro

On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

Biogen

Roche Holding AG

The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that poses a significant and growing threat to global health and economic well-being.

Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche

Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines.

Eli Lilly Stock Analysis: Buy, Hold, or Sell?

Microsoft

After last week's data dump of inflation readings and the Federal Reserve's latest decision to hold interest rates steady, investors can take a deep breath before the next earnings season kicks off in just a few weeks.

News for Eli Lilly Stock (LLY)